Tukaram Karanwad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tukaram Karanwad has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Subham Banerjee
Department of Pharmaceutics National Institute of Pharmaceutical Education and Research (NIPER) Guwahati Assam India
8 shared publications - Umesh Kumar Patil
Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, Madhya Pradesh,470003, India
3 shared publications Abhishek Pawar
Department of Pharmaceutics, National Institute of Pharmaceutical Education & Research (NIPER)-Guwahati, Changsari 781101, Assam, India
2 shared publicationsPrashant Sahu
2 shared publications- Roshan M. Borkar
Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Guwahati, Changsari 781101, India
2 shared publications - Santa Mandal
Faculty of Pharmaceutical Science, Assam Down Town University, Guwahati, India
2 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Elsevier in Disease and Therapeutics
- Vol. 3
Artificial intelligence in the pharmaceutical research and development lifecycle: Applications, ethical challenges, and governance considerations
- 31 October 2026
- Published by Elsevier in Disease and Therapeutics
- Vol. 3
Open AccessArtificial intelligence in the pharmaceutical research and development lifecycle: Applications, ethical challenges, and governance considerations
- 8 September 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (5) , 132
Single-step Sintered 3D-printed Fixed-dose Combined Bilayer Tablets for Compartmentalized Delivery of First-line Anti-tubercular Drugs
- 8 September 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (5) , 132
Single-step Sintered 3D-printed Fixed-dose Combined Bilayer Tablets for Compartmentalized Delivery of First-line Anti-tubercular Drugs
- Open Access
- 1 September 2026
- Published by KEAI Publishing in Journal of Holistic Integrative Pharmacy
- Vol. 7 (3) , 475-487
Emerging self-regulated organic nanogel against osteoarthritis: An expanding horizon towards intelligent diagnosis and therapy
- 1 September 2026
- Published by KEAI Publishing in Journal of Holistic Integrative Pharmacy
- Vol. 7 (3) , 475-487
Open AccessEmerging self-regulated organic nanogel against osteoarthritis: An expanding horizon towards intelligent diagnosis and therapy
- Open Access
- 23 December 2025
- Published by Elsevier in Next Materials
- Vol. 10
Next-generation healthcare: Unveiling the potential of 3D and 4D printing in personalized medicine and medical devices
- 23 December 2025
- Published by Elsevier in Next Materials
- Vol. 10
Open AccessNext-generation healthcare: Unveiling the potential of 3D and 4D printing in personalized medicine and medical devices
- 1 May 2025
- Published by IOP Publishing in Biomedical Materials
- Vol. 20 (3) , 035029
Tuneable dissolution profile of tinidazole through thermoplastic polymer composites in low temperature 3D printing settings for pharmaceutical additive manufacturing applications
Thermoplastic polymeric materials are crucial for powder bed fusion (PBF) based three-dimensional (3D) printing in pharmaceuticals. However, due to limited availability and printability nature of the used feedstocks (either as powder bed materials or composites), underscoring a pressing demand for alternative solutions in pharmaceutical additive manufacturing applications. In this study, the first-time introduction of Kollidon® 25 (K25) thermoplastic polymer, which was not previously explored in PBF-based 3D printing technology, along with the simultaneous usage of Kollidon® SR (KSR) to form a thermoplastic polymer composite for the development of a tunable solid oral dosage form. In addition to this, a novel laser-absorbing dye, i.e. Pigment Green 7, was also introduced to facilitate the laser sintering process of the used thermoplastic polymer composites. Sintered tablets obtained from the used thermoplastic polymer bed composites were systematically characterized using various analytical tools and in vitro examinations as well. The physicochemical characterization of all sintered tablet batches (B1–B7) was within the acceptable limit. Thermal and chemical analyses revealed no detrimental physical or chemical interactions between the components and sintered tablet batches after exposure to laser and temperature. Powder x-ray diffraction diffractograms suggested a change in the native state of tinidazole (TNZ, used as an active pharmaceutical ingredient) to amorphous due to the exposure to sintering parameters. Scanning electron microscopy micrographs of all batches showed intense fusion of the particles in the polymer composite. The sintered tablet batches B1 to B7 exhibited a drug content ranging from 90.36 ± 4.32% to 99.36 ± 1.24%. TNZ released in an acidic medium for up to 2.0 h from different sintered tablets were around 100% to 12% from B1 to B7 batches, respectively following alkaline medium for up to 12.0 h. TNZ release pattern was fine-tuned in accordance with the changes in the composition ratio of K25 and KSR polymers in order to get immediate release to sustained release. This prepared unique thermoplastic pharmaceutical grade polymer composite might broaden the range of materials accessible for PBF-mediated 3D printing in pharmaceutical industrial applications in near future.
- 1 May 2025
- Published by IOP Publishing in Biomedical Materials
- Vol. 20 (3) , 035029
Tuneable dissolution profile of tinidazole through thermoplastic polymer composites in low temperature 3D printing settings for pharmaceutical additive manufacturing applications
Thermoplastic polymeric materials are crucial for powder bed fusion (PBF) based three-dimensional (3D) printing in pharmaceuticals. However, due to limited availability and printability nature of the used feedstocks (either as powder bed materials or composites), underscoring a pressing demand for alternative solutions in pharmaceutical additive manufacturing applications. In this study, the first-time introduction of Kollidon® 25 (K25) thermoplastic polymer, which was not previously explored in PBF-based 3D printing technology, along with the simultaneous usage of Kollidon® SR (KSR) to form a thermoplastic polymer composite for the development of a tunable solid oral dosage form. In addition to this, a novel laser-absorbing dye, i.e. Pigment Green 7, was also introduced to facilitate the laser sintering process of the used thermoplastic polymer composites. Sintered tablets obtained from the used thermoplastic polymer bed composites were systematically characterized using various analytical tools and in vitro examinations as well. The physicochemical characterization of all sintered tablet batches (B1–B7) was within the acceptable limit. Thermal and chemical analyses revealed no detrimental physical or chemical interactions between the components and sintered tablet batches after exposure to laser and temperature. Powder x-ray diffraction diffractograms suggested a change in the native state of tinidazole (TNZ, used as an active pharmaceutical ingredient) to amorphous due to the exposure to sintering parameters. Scanning electron microscopy micrographs of all batches showed intense fusion of the particles in the polymer composite. The sintered tablet batches B1 to B7 exhibited a drug content ranging from 90.36 ± 4.32% to 99.36 ± 1.24%. TNZ released in an acidic medium for up to 2.0 h from different sintered tablets were around 100% to 12% from B1 to B7 batches, respectively following alkaline medium for up to 12.0 h. TNZ release pattern was fine-tuned in accordance with the changes in the composition ratio of K25 and KSR polymers in order to get immediate release to sustained release. This prepared unique thermoplastic pharmaceutical grade polymer composite might broaden the range of materials accessible for PBF-mediated 3D printing in pharmaceutical industrial applications in near future.
- 27 August 2024
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 21 (10) , 5272-5284
Additive Manufacturing of SmartEx QD 100 Designed Oral Three-Dimensional Printlets Containing Isoniazid for Immediate Gastric Release by Selective Laser Sintering
The selection of appropriate materials and compatibility of selected materials with drugs and formulations are limiting steps in three-dimensional printing technology. In this study, SmartEx QD 100 (SM QD 100) was introduced as a novel, coprocessed, unexplored excipient that can be used in SLS-mediated 3D printing. The current study aimed to evaluate the feasibility of fabricating SM QD 100 containing INH-embedded SLS-mediated immediate gastric release tablets. The prepared physical mixtures were subjected to the fabrication of 3D printlets by using SLS-mediated 3D printing. The fabricated 3D printlets were subjected to physicochemical characterization by using various analytical techniques. After oral administration of sintered 3D printlets to rabbits, samples were collected and pharmacokinetic parameters were analyzed using the developed LC-APCI-MS/MS method. The optimized batch was able to release 100% INH within 15 min, which confirmed the immediate gastric release. Similarly, sintered 3D printlets were stable under accelerated stability conditions for three months. Finally, the pharmacokinetic parameters revealed the rate and extent of absorption of INH from sintered 3D printlets. As evidenced by in vitro and in vivo analyses, SM QD 100 was able to sinter SLS-mediated INH-embedded stable immediate gastric release tablets. SM QD 100 is a novel material for SLS-mediated 3D printing in pharmaceutical applications.
- 27 August 2024
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 21 (10) , 5272-5284
Additive Manufacturing of SmartEx QD 100 Designed Oral Three-Dimensional Printlets Containing Isoniazid for Immediate Gastric Release by Selective Laser Sintering
The selection of appropriate materials and compatibility of selected materials with drugs and formulations are limiting steps in three-dimensional printing technology. In this study, SmartEx QD 100 (SM QD 100) was introduced as a novel, coprocessed, unexplored excipient that can be used in SLS-mediated 3D printing. The current study aimed to evaluate the feasibility of fabricating SM QD 100 containing INH-embedded SLS-mediated immediate gastric release tablets. The prepared physical mixtures were subjected to the fabrication of 3D printlets by using SLS-mediated 3D printing. The fabricated 3D printlets were subjected to physicochemical characterization by using various analytical techniques. After oral administration of sintered 3D printlets to rabbits, samples were collected and pharmacokinetic parameters were analyzed using the developed LC-APCI-MS/MS method. The optimized batch was able to release 100% INH within 15 min, which confirmed the immediate gastric release. Similarly, sintered 3D printlets were stable under accelerated stability conditions for three months. Finally, the pharmacokinetic parameters revealed the rate and extent of absorption of INH from sintered 3D printlets. As evidenced by in vitro and in vivo analyses, SM QD 100 was able to sinter SLS-mediated INH-embedded stable immediate gastric release tablets. SM QD 100 is a novel material for SLS-mediated 3D printing in pharmaceutical applications.
- 24 August 2024
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 203, 114471
3D printed tinidazole tablets coupled with melt-extrusion techniques for formulating child friendly medicines
- 24 August 2024
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 203, 114471
3D printed tinidazole tablets coupled with melt-extrusion techniques for formulating child friendly medicines